MediSapiens to Provide Bayer HealthCare Pharmaceuticals With a New Cloud
Computing Application to Analyze and Visualize Multi-Dimensional Genomics Data
HELSINKI, November 5, 2012
HELSINKI, November 5, 2012 /PRNewswire/ --
MediSapiens Ltd, a Finnish company developing web-based data applications for
the pharmaceutical industry, today announced that Bayer HealthCare
Pharmaceuticals has purchased a new software solution developed by
MediSapiens. The software, called OncoGenomics Explorer will provide Bayer
HealthCare Pharmaceuticals with a centralized access to unified global
genomics data for utilization across the entire research organization from
target discovery to drug repositioning.
(Logo: http://photos.prnewswire.com/prnh/20121105/573244 )
"Big Data, a term invented for a collection of data sets so large and complex
that it becomes difficult to process using on-hand database management tools
is quickly becoming increasingly important in pharmaceutical research. Until
now, the lack of software tools that can be adapted to various research
environments has limited the full-scale use of this enormous reservoir of
available data. OncoGenomics Explorer is our answer to this demand," says
Tommi Pisto, CEO of MediSapiens Ltd.
MediSapiens is a bioinformatics company developing inspiring web applications
for genomics researchers, pharmaceutical industry and personalized medicine.
MediSapiens has unique know-how in developing software solutions for
integration of both molecular and clinical data from preclinical models to
interpreting comprehensive molecular profiles of individual cancer patients in
clinical settings. Based on the world's largest unified gene expression
database, MediSapiens platform extends into highly tailored solutions to meet
the exact needs of various demanding research environments.
For more information visit http://www.medisapiens.com or email
Tommi Pisto, CEO, Co-Founder
Tukholmankatu 8 A
Press spacebar to pause and continue. Press esc to stop.